Pharmaceutical company in
Basel

Novartis Stiftung für Mensch und Umwelt

Since 1989 · 11–20 empl.

Novartis Stiftung für Mensch und Umwelt supports Novartis’ social and environmental initiatives, including sponsorship, donations and community engagement. The foundation also addresses health, safety and environmental protection measures and promotes transparency in ethics and compliance.

Rhenochem AG

Since 1990 · 101–500 empl.

Rhenochem AG is a pharmaceutical company offering distribution and sourcing of active pharmaceutical ingredients and finished formulations, together with contract manufacturing and technology transfer. Its services include regulatory support, pharmaceutical logistics, financing assistance and market intelligence.

Dispopharm Services GmbH

Since 1994 · 1–10 empl.

Dispopharm Services GmbH provides services in the international trade of pharmaceuticals and medical products. Its activities include product registration, marketing, promotion and distribution, particularly in sub-Saharan Africa, Central Asia and other markets.

Elanco Tiergesundheit AG

Since 1997 · 21–50 empl.

The core activity of Elanco is the development and manufacture of animal health medicines and products that improve the health, well-being and performance of animals, as well as providing services and solutions for animal health.

Pierre Fabre Pharma SA

Since 1997 · 21–50 empl.

Pierre Fabre Pharma SA develops and markets medicines for dermatological conditions. Its research focuses on paediatric dermatology, oncodermatology and rare skin diseases.

ICON Clinical Research (Switzerland) GmbH

Since 1998 · 11–20 empl.

The company ICON is a service provider to the pharmaceutical industry, focusing on clinical research, medical communication, and market access. The core activities include: * Clinical Research: Conducting clinical trials, including decentralized clinical trials, early-phase studies, and bioanalysis * Medical Communication: Creating medical content, such as publications, presentations, and marketing materials * Market Access: Supporting pharmaceutical companies in launching medicines, including health economics, outcomes research, and market research * Laboratory Services: Bioanalysis, biomarker development and analysis, as well as other laboratory services * Consulting: Strategic consulting for pharmaceutical companies in the areas of clinical research, market access, and medical communication The company also offers specialized services such as risk management, safety reporting, and regulatory affairs.

Mundipharma Medical Company, Hamilton, Bermuda, Basel Branch

Since 2001 · 101–500 empl.

The core activity of Mundipharma is the development, manufacture and marketing of pharmaceutical products, particularly in the field of pain management for cancer patients.

PharmaMar AG

Since 2001 · 11–20 empl.

PharmaMar AG promotes information about antineoplastic treatments in Switzerland and engages with the Swiss scientific community. It provides commercial and scientific information to healthcare professionals about PharmaMar’s product portfolio.

Bayer Consumer Care AG

Since 2005 · 51–100 empl.

Bayer Consumer Care AG is a life science company active in healthcare and agriculture. The company develops and markets products and solutions for human health and agricultural production.

Mundipharma Distribution GmbH

Since 2005 · 1–10 empl.

HetCat PD Dr. Reza Fallahpour

Since 2005 · 1–10 empl.

HetCat PD Dr. Reza Fallahpour is a chemical services provider supplying heterocyclic and aromatic intermediates, metal catalysts, ligands and inorganic salts through an extensive product catalog. The company also offers custom synthesis and contract research from mg to kg scale, including process development, scale‑up and logistics support.

Luye Pharma Switzerland AG

Since 2006 · 11–20 empl.

Luye Pharma Switzerland AG is a pharmaceutical company that develops and manufactures transdermal drug patches and provides CDMO and contract manufacturing services. Its offerings include formulation development and feasibility studies, scale‑up to production, packaging, regulatory support and licensing solutions.

Pierre Fabre (Suisse) S.A.

Since 2006 · 21–50 empl.

Pierre Fabre (Suisse) S.A. operates in the pharmaceutical and dermo-cosmetics sectors. Its activities include developing medicines and care products for cancer, chronic diseases and everyday ailments, as well as products for skin, hair and oral care.

Dr. Reddy's Laboratories SA

Since 2007 · 21–50 empl.

The company's core activity is the development, manufacture and marketing of pharmaceutical products, including generics, biosimilars, over-the-counter products and innovative medicines for various therapeutic areas such as gastroenterology, cardiology, diabetology, oncology, pain management and dermatology.

Rhenopharma AG

Since 2008 · 51–100 empl.

Rhenopharma AG operates in the pharmaceutical sector and provides services across the supply chain. Together with partners, it develops, manufactures, packages and distributes medicines, and also supports activities such as sourcing raw materials, quality control, regulatory approvals, storage and distribution.

Vaximm AG

Since 2008 · 1–10 empl.

The core activity of VAXIMM is the development of oral T-cell immunotherapies for cancer patients.

BioVersys AG

Since 2008 · 21–50 empl.

BioVersys AG is a pharmaceutical company researching and developing medicines for bacterial infections and antimicrobial resistance. It focuses on small molecules with novel modes of action, with development programs that include candidates for resistant hospital infections and tuberculosis.

Rhizen Pharmaceuticals AG

Since 2008 · 51–100 empl.

The core activity of Rhizen Pharmaceuticals AG is the development and marketing of pharmaceuticals, particularly in the field of oncology (cancer treatment) and onco-supportive care. The company focuses on the discovery, development and commercialization of innovative pharmaceuticals that address multiple cancer indications. It has a deep pipeline of assets covering various oncology indications and has expertise in discovery, preclinical development, clinical development and regulatory affairs.

Noorik Biopharmaceuticals AG

Since 2010 · 1–10 empl.

Noorik Biopharmaceuticals AG is a privately owned drug development company focused on repurposing existing drugs and conducting research and development. It is developing a micro-dose formulation of ambrisentan, an endothelin receptor antagonist, for indications including severe COVID-19 pneumonia, portal hypertension and pulmonary arterial hypertension, and has developed novel oral and parenteral formulations, holds second medical use patents and is seeking co-development partners.

Rheinbrands GmbH

Since 2011 · 1–10 empl.

The core activity of RheinBrands GmbH is the development and distribution of innovative consumer healthcare products, particularly in the area of intimate care and wellness products, condoms, medical lubricants and other products for a healthy, clean and hygienic intimate area.

Ironwood Pharmaceuticals GmbH

Since 2012 · 21–50 empl.

Ironwood Pharmaceuticals GmbH is a biopharmaceutical company focused on gastrointestinal diseases. Its activities include developing and commercializing medicines such as linaclotide and evaluating apraglutide as an investigational drug in clinical trials.

NBE-Therapeutics AG

Since 2012 · 21–50 empl.

The core activity of NBE-Therapeutics AG is the development and research of therapeutics, particularly in the field of cancer treatment. The company focuses on the development of antibody-drug conjugates (ADCs) and other therapeutics targeting the fight against cancer cells.

Amyra Biotech AG

Since 2013 · 1–10 empl.

Amyra Biotech AG develops solutions to supplement digestive enzyme activity in the small intestine. Its development pipeline includes consumer health products and prescription medicines intended to support digestion and nutrient absorption.

Mundipharma MEA GmbH

Since 2013 · 1–10 empl.

Mundipharma MEA GmbH is a pharmaceutical company that markets medicines and healthcare products and provides medical information. The company operates pharmacovigilance reporting for side effects and maintains contact channels for media and careers; the website references products such as Betadina and Hedrin.

Mundipharma Near East GmbH

Since 2014 · 101–500 empl.

Mundipharma Near East GmbH develops and markets pharmaceutical products with a focus on cancer pain management and other specialty care therapeutic areas.

Swedish Orphan Biovitrum AG

Since 2014 · 101–500 empl.

The company develops and distributes innovative treatments for rare diseases, particularly in the field of hematology, such as hemophilia and immune thrombocytopenia (ITP). The focus is on improving the lives of patients through access to new therapies and promoting patient-centricity and engagement.

Accense S.A.

Since 2014 · 11–20 empl.

The core activity of Accense is the acquisition, development and marketing of pharmaceutical products, in particular those abandoned by large pharmaceutical companies. The company focuses on reviving and marketing established, safe and effective medicines that are useful for public health. Products include Postafen, Agyrax and Navidoxine, which are distributed in various countries such as France, Scandinavia, Malta and the USA.

Acadia Pharmaceuticals GmbH

Since 2014 · 21–50 empl.

The core activity of Acadia Pharmaceuticals is the development, manufacture and marketing of pharmaceuticals, particularly in the field of neuroscience and rare diseases.

NOUSCOM AG

Since 2015 · 21–50 empl.

The core activity of Nouscom is the development of cancer vaccines, in particular neoantigen-based cancer vaccines for tumors with microsatellite instability.

ABBA Therapeutics AG

Since 2015 · 1–10 empl.

ABBA Therapeutics AG is a biopharmaceutical company specialized in mechanisms of cancer and the development of novel antibody medicines for cancer immunotherapy. The company researches protein targets related to immune checkpoints and develops therapeutic antibodies; a PCT patent application has been submitted for antibodies against one of its targets.

TargImmune Therapeutics AG

Since 2016 · 1–10 empl.

TargImmune Therapeutics AG develops a targeted nucleic acid delivery platform and cancer therapeutics based on it. The approach uses synthetic nanoparticles, and its development programme includes the TAIM compounds TAR001, TAR002 and TAR003.

Ultragenyx Europe GmbH

Since 2016 · 11–20 empl.

Ultragenyx Europe GmbH is a biopharmaceutical company that develops therapies for rare and ultra-rare genetic diseases and researches multiple drug modalities, including gene therapy. The company maintains a clinical pipeline, provides approved medicines such as DOJOLVI and MEPSEVII, and operates patient support programs.

Selmod GmbH

Since 2016 · 11–20 empl.

Selmod GmbH develops anti-infective therapies, particularly antibiotics for infections caused by multidrug-resistant pathogens. The biotechnology company conducts preclinical research and clinical development of drug candidates, including small molecules and peptides, through phase 2 clinical studies.

Luye Pharma Europe AG

Since 2016 · 51–100 empl.

Luye Pharma Europe AG develops and manufactures transdermal therapeutic systems (TTS) and provides CDMO services such as contract development, contract manufacturing, procurement, packaging and regulatory support.

Sumitomo Pharma Switzerland GmbH

Since 2016 · 21–50 empl.

The company's core activity is the development and improvement of healthcare worldwide through innovative research and development, particularly in the fields of biopharmaceuticals and health technology.

Urovant Sciences GmbH

Since 2016 · 1–10 empl.

Urovant Sciences GmbH is a pharmaceutical company focused on research, development and commercialization of therapies in urology, including treatments for overactive bladder such as Vibegron.

EsoCap AG

Since 2017 · 11–20 empl.

EsoCap AG is a clinical-stage biotechnology company developing a platform for targeted drug delivery to the esophagus. Its system uses a capsule to apply a drug-loaded mucoadhesive film to the esophageal lining; its candidate ESO-101 was studied in a Phase II trial for eosinophilic esophagitis.

Versameb AG

Since 2017 · 11–20 empl.

Versameb AG discovers and develops RNA-based therapeutics designed to regulate protein expression. Its pipeline includes drug candidates for conditions including stress urinary incontinence and solid tumors.